Stress-Reducing Interventions in HIV+ Patients: Pilot (PEACH)
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary aim of this project is to examine the efficacy of prolonged exposure (PE) therapy at reducing HIV-related PTSD symptoms, increasing adherence to antiretroviral medication regimens, and increasing health-related quality of life (QOL) in HIV+ patients.
| Condition | Intervention |
|---|---|
|
Stress Disorders, Post-Traumatic HIV Infections |
Behavioral: Prolonged Exposure Therapy |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Pilot Intervention for PTSD, Nonadherence, and HIV Risk |
- PTSD symptoms [ Time Frame: pre- & post-intervention, 3-month post, & 6-month post ] [ Designated as safety issue: No ]
- Adherence to HIV medications [ Time Frame: pre- & post-intervention, 3-month post, & 6-month post ] [ Designated as safety issue: No ]
- Health-related Quality of Life [ Time Frame: pre- & post-intervention, 3-month post, & 6-month post ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 70 |
| Study Start Date: | April 2005 |
| Estimated Study Completion Date: | February 2010 |
| Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Prolonged Exposure Therapy.
|
Behavioral: Prolonged Exposure Therapy
Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
|
|
No Intervention: 2
Weekly monitoring/Waitlist Control Group.
|
Detailed Description:
HIV+ patients will be randomized to receive either PE therapy (up to 18 possible sessions) or weekly symptom monitoring (described below) and will complete measures of PTSD, adherence, and QOL pre- and post-intervention and at 3- and 6-month follow-up assessments. Secondary analyses will examine the impact of the intervention on disorders commonly comorbid with PTSD (i.e., anxiety, mood, and substance abuse/dependence disorders).
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Must be HIV+
- Must meet PTSD diagnostic criteria
- Must be taking HIV medications
- Must be able to read and write in English
Exclusion Criteria:
- Current or previous diagnosis of schizophrenia, any current diagnosis with psychotic features, or current suicidal ideation
- Being in a current abusive relationship or ongoing intimate relationship with one's assailant
- Mental retardation
Contacts and Locations| United States, Ohio | |
| Violet's Cupboard | |
| Akron, Ohio, United States, 44310 | |
| AIDS Taskforce of Greater Cleveland | |
| Cleveland, Ohio, United States, 44115 | |
| Principal Investigator: | Douglas L Delahanty, PhD | Kent State University |
More Information
No publications provided
| Responsible Party: | Douglas L. Delahanty, Professor, Kent State University |
| ClinicalTrials.gov Identifier: | NCT00599599 History of Changes |
| Other Study ID Numbers: | R34 MH071201-01A1, NIMH, 1 R34 MH071201-01A1 |
| Study First Received: | January 11, 2008 |
| Last Updated: | March 4, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Kent State University:
|
Prolonged Exposure Therapy Adherence to HIV Medications Complementary Therapies |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Stress Disorders, Post-Traumatic Stress Disorders, Traumatic Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Anxiety Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 16, 2013